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The pons region of the Alzheimer’s disease (AD) brain is one of the last to show amyloid-𝛽 (A𝛽) deposits and has been suggested to
contain neuroprotective compounds. Kisspeptin (KP) is a hormone that activates the hypothalamic-pituitary-gonadal axis and has
been suggested to be neuroprotective against A𝛽 toxicity. The localization of KP, plus the established endogenous neuroprotective
compounds corticotropin releasing hormone (CRH) and catalase, in tissue sections from the pons region of a male AD subject has
been determined in relation to A𝛽 deposits. Results showed A𝛽 deposits also stained with KP, CRH, and catalase antibodies. At
high magnification the staining of deposits was either KP or catalase positive, and there was only a limited area of the deposits with
KP-catalase colocalization. The CRH does not bind A𝛽, whilst both KP and catalase can bind A𝛽, suggesting that colocalization
in A𝛽 deposits is not restricted to compounds that directly bind A𝛽. The neuroprotective actions of KP, CRH, and catalase were
confirmed in vitro, and fibrillar A𝛽 preparations were shown to stimulate the release of KP in vitro. In conclusion, neuroprotective
KP, CRH, and catalase all colocalize with A𝛽 plaque-like deposits in the pons region from a male AD subject.
1. Introduction
Thedeposition of the amyloid-𝛽 (A𝛽) peptide within plaques
in the Alzheimer’s disease (AD) brain is a central feature of
the disease pathology [1, 2]. A sequential pattern of A𝛽
deposition within different regions of the brain has been
suggested as AD progresses [3–6]. The staging of A𝛽 depo-
sition by Thal et al. (2002) [3] identified the cerebellum
plus brainstem nuclei including the pons as the last to show
A𝛽 deposits. In transgenic mice overexpressing the human
amyloid precursor protein (APP) the A𝛽 deposition showed
a similar sequential pattern, with the cerebellum and pons
again the last to showA𝛽 deposits [7].The apparent resistance
of the cerebellum and pons to neurodegenerative changes
suggests that endogenous neuroprotective processesmay play
a role in these tissues.
A range of endogenous compounds have been suggested
to have neuroprotective properties against A𝛽 in AD models
[8–16]. In a recent study kisspeptin (KP) peptides were sug-
gested to have neuroprotective properties against A𝛽 plus
related amyloid proteins [17]. The KP peptide is a reproduc-
tive hormone [18], and the female hypothalamic levels of KP
show elevations after menopause that are not seen in males
[19]. Female AD onset is typically postmenopausal, and there
is significantly less neurodegeneration in the hypothalamus
in women compared to men [20]. The release of KP from
human neuronal cells has been shown to be stimulated by A𝛽
[17] suggesting that in regions that express the KiSS-1 gene,
which encodes for the KP peptides, there may be changes in
KP levels in AD due to the elevations of A𝛽.
The KP peptide was identified as having similarity to the
catalase region that bindsA𝛽 [21], andKP bindsA𝛽 itself [17].
Catalase has been shown to bind directly to A𝛽 fibrils [22]
and has been found by immunohistochemistry in amyloid
plaques in AD brains [23]. The catalase enzyme has been
shown to have neuroprotective properties as an antioxidant
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enzyme [24, 25], as an A𝛽 binding protein [26, 27] and when
targeted to the mitochondria as a modifier of A𝛽 secretion
[12]. The CRH peptide has well-established neuroprotective
properties and prevents A𝛽 toxicity [10, 28–33]. The mecha-
nism for CRH neuroprotection, unlike KP neuroprotection,
is receptor mediated [30–32], and the peptide does not bind
A𝛽, unlike catalase and KP [17, 26]. In AD the CRH peptide
has been found to be associated with thioflavin S-positive
deposits [34], and the levels of CRH are markedly reduced
in some brain regions [35, 36].
The KP peptide [37, 38], CRH peptide [39], and catalase
[40, 41] are all found in the pons, where neurodegenerative
changes and A𝛽 deposition occur in the latter stages of the
disease [3, 7]. In this study the localization of immunoreactive
(ir-) KP,CRH, and catalase in relation toA𝛽deposits has been
determined in pons sections from a male AD patient. The
neuroprotective effects of KP, CRH, and catalase plus ir-KP
release from human SH-SY5Y neuroblastoma cells have also
been studied.
2. Materials and Methods
2.1. Materials. Pons sections from a 72-year-old male with
AD (Cat. no. ab4586; Lot no. B506287) and a 26-year-old
normal male (Cat. no. ab4316; Lot no. A504234) and BAM-10
mouse anti-A𝛽 antibody were obtained from Abcam PLC,
Cambridge, UK. Rabbit anti-KP 45–54 antiserum, KP 1–54,
KP 42–54, KP 45–54, KP 45–50, neuropeptide-FF (NPFF),
CRH, A𝛽 1–46, A𝛽 1–43, A𝛽 1–42, A𝛽 1–40, A𝛽 1–38, and
A𝛽 17–40 were purchased from Bachem AG, Switzerland.
Goat anti-mouse IgG Alexa Fluor 568 and goat anti-rabbit
IgG Alexa Fluor 488 were purchased from Chemicon, UK.
VECTASHIELD Mounting Media was purchased from Vec-
tor Laboratories Ltd., UK. The CAT-505 mouse anti-catalase
antibody, alkaline phosphatase conjugated goat anti-rabbit
IgG, alkaline phosphatase conjugated anti-mouse IgG, and
all other chemicals were purchased from Sigma-Aldrich, UK.
2.2. A𝛽 Fibril Formation. Batches of synthetic A𝛽 1–46, A𝛽 1–
43, A𝛽 1–42, A𝛽 1–40, A𝛽 1–38, A𝛽 17–40, or A𝛽 25–35 were
dissolved in distilled water at a concentration of 1.0mg/mL
and incubated at 37∘C for 24 h, with constant oscillation.
Following incubation, the formation of fibrils was confirmed
byTEMorCongo red assay as previously described byMilton
and Harris [22, 42, 43].
2.3. Antibody Characterization. NUNC MaxiSorp 96-well
immunoplates were coated with 1 𝜇g/mL of either KP pep-
tides, NPFF peptides, CRH peptides, catalase, or A𝛽 peptides
in 50mM carbonate buffer, pH 9.6, and unoccupied sites
blocked with 0.2% (w/v) marvel. Either the BAM-10 mouse
anti-A𝛽 antibody [44], rabbit anti-A𝛽 21–32 antiserum [45],
rabbit anti-KP 45–54 antiserum [17], KCHMB001 mouse
anti-CRH antibody [46–48], or CAT-505mouse anti-catalase
antibody [49] at a final concentration of 0.1𝜇g/mL in 50mM
TRIS (containing 0.1% BSA and 0.1% Triton X-100) was
added (100 𝜇L/well) and incubated at 4∘C for 16 hours.
Some plates were coated with A𝛽 1–42 fibrils, prepared, and
tested as described by Milton and Harris (2009) [22], and
these plates were preincubated at 4∘C for 24 hours with
KP 45–54, NPFF, CRH or catalase prior to addition of
antibodies. After washing to remove unbound material an
alkaline phosphatase conjugated goat anti-rabbit or anti-
mouse secondary antibody was added and incubated at 24∘C
for 2 hours. After washing to remove unbound material p-
nitrophenylphosphate substrate was added and absorbance at
405 nm determined.
2.4. Immunohistochemistry and Confocal Microscopy. Pre-
mounted and paraffin-embedded pons tissue sections from
a normal or an AD patient at a thickness of 5𝜇M were used.
The tissue had been examined and diagnosed by a licensed
pathologist and was ethically obtained. The sections were
processed for immunostaining [50] and incubated overnight
at 4∘C with 1 : 1000 dilutions (1 𝜇g/mL final concentration)
of BAM-10 mouse anti-A𝛽 antibody [44], rabbit anti-A𝛽
21–32 antiserum [45], rabbit anti-KP 45–54 antiserum [17],
KCHMB001 mouse anti-CRH antibody [46–48], and CAT-
505 mouse anti-catalase antibody [49] in phosphate buffered
saline containing 0.01% Tween 20 (PBST). For some of the
incubations with anti-KP 45–54 the antibody solutions were
preincubatedwithNPFF (10 𝜇g/mL) for 24 h to block binding
to endogenous NPFF [51]. The sections were then washed for
3 × 5min with PBST before the secondary antibodies were
applied (goat anti-mouse IgG-Alexa Fluor 568 and goat anti-
rabbit IgG-Alexa Fluor 488, 1 : 500) for 1 hour. The sections
were thenwashed inPBST, and cover slipsweremountedwith
VECTASHIELDMounting Media.
Images were acquired by sequential scanning using a
Leica TCS SP2 confocal system (Leica Microsystems, Milton
Keynes, UK) with a 63x ceramic dipping objective. A 488 nm
laser was used for excitation of Alexa Fluor 488 labeled goat
anti-rabbit IgG, while a 543 nm laser was used for Alexa Fluor
568 labeled goat anti-mouse IgG excitation [52].
2.5. Cell Cultures. Human SH-SY5Y neuroblastoma cells
were routinely grown in a 5% CO
2
humidified incubator at
37∘C in a 1 : 1 mixture of Dulbecco’s modified Eagle’s medium
and HAM’s F12 with Glutamax (Invitrogen) supplemented
with 10% fetal calf serum (FCS), 1% nonessential amino acids,
penicillin (100 units/mL), and streptomycin (100mg/mL)
[53]. Human neuroblastoma SH-SY5Y cells were cultured in
6-well or 96-well plates and differentiated with retinoic acid
for 7 days prior to experimentation.
2.6. KP Release. 2.5× 105 differentiated SH-SY5Y cells/well in
6-well plates were incubated in 4mL of medium containing
a subtoxic dose (100 nM) of either fibrillar A𝛽 1–46, A𝛽 1–43,
A𝛽 1–42, A𝛽 1–40, A𝛽 1–38, A𝛽 17–40, or A𝛽 25–35 for 4 h.
Control cells were cultured in medium alone. Media was
harvested and KP extracted using a polyclonal anti-KP 45–54
antiserum and a protein-A agarose column. The immuno-
reactive KP was eluted from the column in 0.5M acetic acid
and was further purified using a Sep-Pak C
18
extraction step.
The Sep-Pak C
18
columns were prewetted with methanol and
0.5M acetic acid, acidified samples applied, and columns
washed with 0.5M Acetic acid prior to elution of bound
peptide with 70% acetonitrile. After drying under a stream
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of nitrogen, samples were resuspended in PBS containing
0.1% BSA plus 0.05% Tween 20.
2.7. Determination of ir-KP. ELISA plates were coated with
1 𝜇g/mL anti-KP 45–54 antiserum in 50mMcarbonate buffer,
pH 9.6, and unoccupied sites blocked with 5% (w/v) marvel.
Samples or synthetic KP 45–54 standards (0–1000 pg/mL)
were applied in assay buffer (PBS containing 0.1% BSA plus
0.05% Tween 20) and incubated for 24 h. After washing with
assay buffer to remove unbound material, biotinyl-KP 45–50
(10 ng/mL) was added and incubated for 2 h. After washing
to remove unbound material, immunoreactive- (ir-) KP-
like material was detected using a streptavidin-horseradish
peroxidase conjugate and 3,3󸀠,5,5󸀠-tetramethylbenzidine sub-
strate [17]. Sample levels were compared to KP 45–54 stan-
dards and ir-KP-like peptide levels expressed as a% of control
cell release.
2.8. Effect of KP, CRH, and Catalase on A𝛽 Neurotoxicity.
On the day of the experiment 5× 103 differentiated SH-
SY5Y cells/well in 96-well plates were pretreated with either
media alone (control) or anti-KP 45–54 antibody (10 𝜇g/mL)
to block endogenous KP, KCHMB001 anti-CRH antibody
(10 𝜇g/mL) to block endogenous CRH, or 3-aminotriazole
(3AT: 50 𝜇M) to inhibit endogenous catalase [24, 53] for a
4 h period. The A𝛽 1–42 (10 𝜇M) was then added to induce
toxicity, and cells were incubated for 16 hours prior to
determination of cell viability. In experiments to assess the
neuroprotection byKP, CRH, or catalase theKP 1–54 (10𝜇M),
CRH (10 nM), or catalase (5𝜇g/mL) was incubated for 4 h
with the A𝛽 1–42 (10 𝜇M) to allow binding to occur prior
to addition to cells. The mixtures of A𝛽 1–42 plus either
media alone or KP 1–54, CRH, or catalase were added to
cells to induce toxicity and incubated for 16 hours prior to
determination of cell viability.
2.9. Cell Viability. After treatment with test peptides or drugs
and incubation for the appropriate time, the viability was
determined by MTT reduction [21]. After incubation with
test substances, MTT (10 𝜇L : 12mM stock) was added and
cells incubated for a further 4 hours. Cell lysis buffer
(100 𝜇L/well; 20% (v/v) SDS, 50% (v/v) N,N-dimethylforma-
mide, pH 4.7) was added, and after repeated pipetting to lyse
cells, the MTT formazan product formation was determined
by measurement of absorbance change at 570 nm. Control
levels in the absence of test substanceswere taken as 100% and
the absorbance in the presence of cells lysedwithTritonX-100
at the start of the incubation periodwith test substances taken
as 0% [54].
2.10. Data Analysis. All data are expressed as means ± SEM
for ir-KP measurements levels in samples were determined
from a standard curve using synthetic KP 45–54 as the
standard. For cytotoxicity experiments data are expressed
as % control cells (MTT reduction). Statistical analysis was
performed by one-way analysis of variance (ANOVA) with
Tukey orDunnettmultiple comparison post hoc testing using
GraphPad Prism software (version 6), with a 𝑃 value of <0.05
considered statistically significant.
3. Results
3.1. Characterization of Antibodies. The binding of BAM-10
mouse anti-A𝛽 antibody [44], rabbit anti-A𝛽 21–32 antiserum
[45], rabbit anti-KP 45–54 antiserum [17], CAT-505 mouse
anti-catalase antibody [49], and KCHMB001 mouse anti-
CRH antibody [46] to A𝛽, KP, NPFF, catalase, and CRH was
tested. Both of anti-A𝛽 antibodies, BAM-10 mouse anti-A𝛽
and rabbit anti-A𝛽 21–32, showed significant binding to full
lengthA𝛽 but not toKP,NPFF, catalase, or CRH (Figure 1(a)).
The BAM-10 antibody did not bind A𝛽 17–40 in agreement
with the published specificity of this antibody for A𝛽 1–12 [44,
55, 56], whilst the anti-A𝛽 21–32 antibody showed significant
binding to A𝛽 17–40. The anti-KP 45–54 antibody showed
significant binding toKP 1–54 plusKP 45–54 and also showed
significant binding to NPFF but did not cross-react with A𝛽,
catalase, or CRH (Figure 1(a)). The CAT-505 anti-catalase
antibody showed significant binding to catalase and showed
no cross-reactivity with A𝛽, KP, NPFF, or CRH peptides.The
KCHMB001 anti-CRH antibody showed significant binding
to CRH and showed no cross-reactivity with A𝛽, KP, NPFF
or catalase.
The BAM-10 anti-A𝛽, anti-A𝛽 21–32, and anti-KP 45–54
antibodies all showed significant binding to plates coatedwith
A𝛽 1–42 fibrils and pretreated with KP 45–54 (Figure 1(b)).
The BAM-10 anti-A𝛽 and anti-A𝛽 21–32 antibodies but not
the anti-KP 45–54 antibody showed significant binding to
plates coated with A𝛽 1–42 fibrils and pretreated with NPFF
(Figure 1(b)).This observation contrasts with the cross-react-
ivity of the anti-KP 45–54 antibody with NPFF (Figure 1(a))
and suggests either that no specific binding of NPFF to A𝛽
had occurred or that the epitope of NPFF recognized by the
antibody is inaccessible for antibody binding when the NPFF
is bound to A𝛽. The CAT-505 anti-catalase antibody showed
no significant binding to plates coated with A𝛽 1–42 fibrils
and pretreated with either KP 45–54 or NPFF (Figure 1(b)).
The BAM-10 anti-A𝛽, anti-A𝛽 21–32, and CAT-505 anti-cata-
lase antibodies showed significant binding to plates coated
withA𝛽 1–42 fibrils and pretreatedwith catalase (Figure 1(b)).
The anti-KP 45–54 antibody showed no binding to plates
coated with A𝛽 1–42 fibrils and pretreated with catalase
(Figure 1(b)). The KCHMB001 anti-CRH antibody showed
no significant binding to plates coated with A𝛽 1–42 fibrils
or those pretreated with either CRH, KP 45–54, NPFF, or
catalase (Figure 1(b)), suggesting that either no specific
CRH binding to A𝛽 had occurred or that the epitope of
CRH recognized by the antibody is inaccessible for antibody
binding when the CRH is bound to A𝛽. The BAM-10 anti-A𝛽
and anti-A𝛽 21–32 antibodies showed significant binding
tolinebreak plates coated with A𝛽 1–42 fibrils and pretreated
with CRH (Figure 1(b)).
3.2. Double-Labeling Immunohistochemistry for KP and A𝛽
in a Normal Control. Immunohistochemistry analysis with
anti-KP 45–54 alone in pons sections from a 26-year-old
normal male (Cat. no. ab4316; Lot no. A504234) showed
staining that was detectable with green fluorescence but
not red fluorescence. Immunohistochemistry analysis with
BAM-10 anti-A𝛽 alone showed staining that was detectable
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Figure 1: Binding of anti-A𝛽, anti-KP, anti-catalase and anti-CRH antibodies to A𝛽, KP, NPFF, catalase and CRH. In (a) plates were
coated with A𝛽 1–42, A𝛽 17–40, KP 1–54, KP 45–54, NPFF, catalase, and CRH. Binding of BAM-10 mouse anti-A𝛽 antibody (open
columns), rabbit anti-A𝛽 21–32 antiserum (closed columns), rabbit anti-KP 45–54 antiserum (open hatched columns), CAT-505 mouse
anti-catalase antibody (closed hatched columns) and KCHMB001 mouse anti-CRH antibody (open cross-hatched columns) was detected
using alkaline phosphatase conjugated secondary antibodies and p-nitrophenylphosphate substrate. In (b) plates coated with A𝛽 1–42 fibrils
were preincubated with KP 45–54, NPFF, catalase, or CRH before addition of BAM-10 mouse anti-A𝛽 antibody (open columns), rabbit
anti-A𝛽 21–32 antiserum (closed columns), rabbit anti-KP 45–54 antiserum (open hatched columns) and CAT-505 mouse anti-catalase
antibody (closed hatched columns), KCHMB001 mouse anti-CRH antibody (open cross-hatched columns). Binding was detected using
alkaline phosphatase conjugated secondary antibodies and p-nitrophenylphosphate substrate. Results are expressed as mean ± SEM (𝑛 = 8)
absorbance change at 405 nm. (∗ = 𝑃 < 0.05 versus control; one-way ANOVA).
with red fluorescence but not green fluorescence. Control
incubations with secondary antibodies showed no detectable
staining above background. The results from the double-
labeling immunohistochemistry showed staining of tissue
with the anti-KP 45–54 (Figure 2(a)) and BAM-10 anti-A𝛽
(Figure 2(b)) antibodies. There was no colocalization of anti-
KP45–54 andBAM-10 anti-A𝛽 labeling observed in the tissue
(Figure 2(c)).
3.3. Double-Labeling Immunohistochemistry for KP and A𝛽
in AD. The results from the double-labeling immunohisto-
chemistry in the pons sections from a 72-year-old male with
AD (Cat. no. ab4586; Lot no. B506287) show that the anti-
KP 45–54 (Figure 3(a)) and BAM-10 anti-A𝛽 (Figure 3(b))
antibodies labeled deposits. The anti-KP 45–54 staining was
shown to colocalize with the BAM-10 anti-A𝛽 labeling in the
plaque-like deposits (Figure 3(c)). The KP labeling was unal-
tered by preincubation of the antibody with NPFF [51] (Fig-
ures 3(d), 3(e), and 3(f)), and colocalization with the BAM-10
anti-A𝛽 labeling was still observed. The colocalization of KP
andA𝛽 appeared to be confined to plaque-like deposits rather
than throughout the tissue (Figures 3(c) and 3(f)). Control
incubations with secondary antibodies showed no detectable
staining or colocalization in plaque-like deposits above the
background for green fluorescence (Figures 3(g) and 3(i)) or
red fluorescence (Figures 3(h) and 3(i)).
3.4. Double-Labeling Immunohistochemistry for CRH and A𝛽.
To confirm the observations of Powers et al. (1987) [34]
that CRH is present in AD amyloid plaques double labeling
immunohistochemistry with a polyclonal anti-A𝛽 21–32 anti-
body and the KCHMB001 monoclonal anti-CRH antibody
was carried out. The results showed labeling with both anti-
bodies and colocalization of the A𝛽 and CRH in plaque-like
deposits (Figures 4(a), 4(b) and 4(c)). The A𝛽 labeling with
the anti-A𝛽 21–32 polyclonal primary antibody (Figure 4(b))
showed a similar pattern of A𝛽 labeling to that seen with the
BAM-10 monoclonal anti-A𝛽 antibody (Figure 3(b)).
3.5. Double-Labeling Immunohistochemistry for Catalase and
A𝛽. To confirm the observations of Pappolla et al. (1992)
[23] that catalase is present in AD amyloid plaques double-
labeling immunohistochemistry with a polyclonal anti-A𝛽
21–32 antibody and the CAT-505 monoclonal anti-catalase
antibody was carried out. The results showed labeling with
both antibodies and colocalization of the A𝛽 and catalase in
plaque like deposits (Figures 5(a), 5(b), and 5(c)).
3.6. Double-Labeling Immunohistochemistry for KP and
Catalase. The lack of A𝛽 positive deposits that did not
show KP or catalase labeling suggested that the two com-
pounds might colocalize in the plaques. Double-labeling
immunohistochemistry results showed that this was the case
Journal of Neurodegenerative Diseases 5
Anti-KP
(a)
Anti-Aß
(b)
Anti-KP Anti-Aß
(c)
Figure 2: Double-labeling immunofluorescence demonstrating colocalization of kisspeptin (KP) and amyloid-𝛽 (A𝛽) in the pons of a normal
control (a–c). KP appears green, and A𝛽 appears red. The overlap of KP and A𝛽 appears yellow. Bars = 50𝜇m.
Anti-KP
(a)
Anti-Aß
(b)
Anti-KP Anti-Aß 
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(d)
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(e)
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Control 488
(g)
Control 568
(h)
Control 488 Control 568
(i)
Figure 3: Double-labeling immunofluorescence demonstrating colocalization of kisspeptin (KP) and amyloid-𝛽 (A𝛽) in the pons in
Alzheimer’s disease (a–f). Staining due to nonspecific binding of secondary antibodies is shown in (g–i). KP appears green, and A𝛽 appears
red. The overlap of KP and A𝛽 appears yellow, and examples are labeled with arrows in (c) and (f). Bars = 50 𝜇m.
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Anti-CRH
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(b)
Anti-CRH Anti-Aß
(c)
Figure 4: Double-labeling immunofluorescence demonstrating colocalization of CRH and A𝛽 in the pons in Alzheimer’s disease (a–c). CRH
appears red, and A𝛽 appears green.The overlap of CRH and A𝛽 appears yellow, and an example is labeled with an arrow in (c). Bars = 50 𝜇m.
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(c)
Figure 5: Double-labeling immunofluorescence demonstrating colocalization of catalase and A𝛽 in the pons in Alzheimer’s disease (a–c).
Catalase appears red, and A𝛽 appears green. The overlap of catalase and A𝛽 appears yellow, and an example is labeled with an arrow in (c).
Bars = 50𝜇m.
(Figures 6(a), 6(b), and 6(c)). Of interest was the observation
at higher magnification that there appeared to be specific
KP and catalase sites with only limited colocalization within
plaque-like deposits (Figures 6(d), 6(e), and 6(f)).
3.7. Fibrillar A𝛽 Stimulation of KP Release. The effects of
fibrillar A𝛽 peptides on endogenous KP release were tested
using human SH-SY5Y neurons. The assay used cross-reacts
with KP 1–54, KP 27–54, KP 42–54, KP 45–54, and KP 45–
50 but not KP 47–50 or NPFF. Results showed that fibrillar
A𝛽 1–46, A𝛽 1–43, A𝛽 1–42, A𝛽 1–40, A𝛽 1–38, A𝛽 17–40,
and A𝛽 25–35 all stimulated a significant 3-4-fold increase,
from a basal level of 10.5± 0.6 pg/mL, in ir-KP release from
SH-SY5Y neurons during a 4-hour incubation (Figure 7(a)).
A dose response curve for fibrillar A𝛽 1–42 stimulated ir-
KP release showed that at doses above 100 nM there was a
significant increase in ir-KP release (Figure 7(b)). At the two
highest doses (1 𝜇M and 10 𝜇M) there was significant ir-KP
release; however, this was accompanied by neurotoxicity, and
it is likely that the higher levels may be due to KP released
from dead cells rather than KP directly stimulated by A𝛽.
3.8. Effect of KP, CRH, andCatalase on Fibrillar A𝛽 1–42 Toxic-
ity. In order to inhibit endogenous KP, CRH, and catalase the
effects of the anti-KP 45–54 antibody, the KCHMB001 anti-
CRH antibody, and the catalase inhibitor 3AT on fibrillar A𝛽
1–42 toxicity were tested using human SH-SY5Yneurons.The
results showed that both the anti-KP 45–54 antibody and the
catalase inhibitor 3AT caused a significant enhancement of
A𝛽 1–42 toxicity (Figure 8(a)), whilst the KCHMB001 anti-
CRH antibody had no effect.
The direct effects of the KP 1–54, CRH, and catalase
on fibrillar A𝛽 1–42 toxicity were also tested using human
SH-SY5Y neurons. The results showed that the KP 1–54,
CRH, and catalase were all able to prevent A𝛽 neurotoxicity
(Figure 8(b)).
4. Discussion
The colocalization of KP with A𝛽 in plaque-like deposits
(Figure 3) is a novel observation. The colocalization of CRH
with A𝛽 confirms the observations of Powers et al. (1987)
[34] and the colocalization of catalase with A𝛽 confirms the
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Figure 6: Double-labeling immunofluorescence demonstrating colocalization of KP and catalase in the pons in Alzheimer’s disease (a–f).
KP appears green, and catalase appears red. The overlap of KP and catalase appears yellow (merge), and an example is labeled with an arrow
in (c).The arrows labeled 1 correspond to an example of KP only labeled in (d) and (f); arrows labeled 2 correspond to an example of catalase
only label in (e) and (f); and arrows labeled 3 correspond to an example of KP and catalase colocalizing in (d), (e), and (f). Bars = 50𝜇m
(a)–(c) and 5 𝜇m (d)–(f).
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Figure 7: Effects of fibrillar A𝛽 peptides on ir-KP release from SH-SY5Y neurons. (a) Neuronal SH-SY5Y cell cultures were exposed to
fibrillar A𝛽 1–43, A𝛽 1–42, A𝛽 1–40, A𝛽 1–38, A𝛽 17–40, and A𝛽 25–35 peptides (100 nM each) for 4 h. (b) Dose dependent release of ir-KP
was determined by incubating SH-SY5Y cell cultures with fibrillar A𝛽 1–42 (0–10𝜇M) for 4 h.The release of ir-KP into the cell culture media
was determined by EIA. All results, as % control (media alone), are shown as the mean ± SEM (𝑛 = 8) (∗: 𝑃 < 0.05 versus control (media
alone); one-way ANOVA).
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Figure 8: Effects of KP, CRH, and catalase on A𝛽 toxicity in SH-SY5Y neurons. (a) Neuronal SH-SY5Y cell cultures were exposed to 10 𝜇g/mL
anti-KP 45–54 antibody (hatched columns), 10 𝜇g/mL anti-CRH antibody (cross-hatched columns), or 50 𝜇M 3AT (stippled columns) for 4
hours prior to addition of media (open columns) or fibrillar A𝛽 1–42 (10𝜇M: closed columns). (b) Neuronal SH-SY5Y cell cultures were
exposed to 10𝜇MKP 1–54 (hatched columns), 10 nM CRH (crosshatched columns), or 5 𝜇g/mL catalase (stippled columns) plus media alone
(open columns) or fibrillar A𝛽 1–42 (10𝜇M: closed columns). After incubation for 16 hours, cell viability was determined by the MTT assay.
All results are expressed as a % control (SH-SY5Y cells in media alone) and are expressed as the mean ± SEM (𝑛 = 8) (∗: 𝑃 < 0.05 versus
control (media alone); †: 𝑃 < 0.05 versus amyloid fibrils alone; one-way ANOVA).
observations of Pappolla et al. (1992) [23].The failure of CRH
to directly bind A𝛽 (Figure 1(b)) confirms previous studies
[26, 31] and raises the possibility that the colocalization
could be due to either the peptide being trapped within the
extracellular debris, that is, part of the amyloid plaques, or
that it binds to another component of the plaques. It is not
possible from these studies to determine whether the KP
in the A𝛽 positive deposits has directly bound the A𝛽 as
described by Milton et al. (2012) [17] or whether it is trapped
in the plaque debris. Both KP and catalase bind fibrillar forms
of A𝛽 [17, 22]. The lack of secondary antibody binding to the
plaque-like deposits suggests that the localization of KP, CRH
catalase, and A𝛽 observed in these studies is due to direct
binding of the primary antibodies to the respective proteins
in the deposits. In the case of KP there is a known cross-
reactivity of KP 45–54 antibodies with NPFF [51]; however,
preadsorption of the antibody with NPFF peptide did not
reduce the binding, suggesting that the KP is authentic mate-
rial and not NPFF. Further studies are required to confirm
these findings and also determine the regional expression
of KP in AD. Changes in hypothalamic KP expression have
previously been documented in women at menopause [19],
and it is well known that the KiSS-1 expression is regulated
by estrogen [57]. The estrogen regulation of KiSS-1 and KP
peptides also differs between different brain regions [58–
60], and it has been suggested that the expression patterns
of the 𝛼 and 𝛽 estrogen receptors are responsible for this
[61]. The expressions of the 𝛼 and 𝛽 estrogen receptors are
also changed in AD [62], and this in turn may alter KiSS-
1 expression and KP levels. The contribution of the cell
surface G-protein-coupled estrogen receptor (GPR30) to KP
regulation is unknown, but this form has been found in
hippocampal tissue [63, 64] and could contribute to changes
seen after menopause.
The KP peptides have been shown to be released from
human SH-SY5Y neuroblastoma cells in response to fibrillar
A𝛽 forms (Figure 7) and have previously been shown to be
released by other amyloid-fibril forming peptides when in a
fibrillar form [17]. The doses of amyloid-fibril forming pep-
tides used previously were subtoxic [17] and selected based on
the most toxic fibrillar amyloid peptide; in the current study
we also show significant increases in KP release in response
to toxic doses. The reduced release at the highest dose of
A𝛽 tested corresponds to a significant toxicity during the
incubation time andmay be caused by the release of degrada-
tive enzymes from dead cells. The levels of KP released are
relatively low and suggest that the neuroprotection observed
with toxic doses of fibrillar A𝛽 is more likely to be recep-
tor mediated rather than via a direct A𝛽 binding action.
However, in previous studies the KP receptor antagonist or
the NPFF receptor antagonist, which blocks some actions
of KP [65–67], had no effect on KP neuroprotection [17]. A
recent study suggests that the NPFF antagonist RF9 used in
previous studies does not block all of the actions of NPFF
[68] and these peptides are known to activate acid sensing
ion channels (ASICs) in a nonreceptor mediated action [69].
Our observations that KP is present in the pons region of an
AD brain suggest that KP neuroprotection could occur in an
AD setting, and further studies into the mechanism of action
of KP may define the mechanism of action.
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The protective roles of catalase are well documented [12,
24–27], and here we confirm enhancement of fibrillar A𝛽
toxicity by the catalase inhibitor 3AT plus protection against
A𝛽 toxicity by catalase (Figure 8).The CRH protection is also
well documented [10, 28–33] and here is only seenwith added
CRH in the SH-SY5Ymodel. In the pons of AD there are both
catalase andCRHcolocalizationwithA𝛽deposits, suggesting
potential neuroprotective roles for catalase or CRH.
5. Conclusion
In conclusion, we present evidence of colocalization of KP,
CRH, and catalase in A𝛽 positive plaque-like deposits in the
pons of the AD brain. The in vitro observations that fibrillar
A𝛽 stimulates ir-KP release and that both endogenousKP and
catalase are neuroprotective suggest potential neuroprotec-
tive roles in AD. The colocalization study is the first demon-
stration of an interaction of KP with A𝛽 in an in vivo AD
setting and suggests a potential role for KP in AD pathology.
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